- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00382928
Automatic External Defibrillation Monitoring in Cardiac Arrest
We propose to randomize automatic external cardioverter/defibrillators (AECD) in patients who are at high risk for life-threatening abnormal heart rhythms (arrhythmias) and are admitted to the telemetry ward, all other treatments being constant including cardiopulmonary resuscitation.
We hypothesize that the automatic, rapid, accurate and specific diagnostic and therapeutic technology used in AECDs will further increase the rate of survival in patients with cardiac arrest through rapid and automatic defibrillation, independent of operator initiation, as compared to standard cardiopulmonary resuscitation initiated by healthcare providers.
Study Overview
Status
Intervention / Treatment
Detailed Description
Cardiac arrest (CA) is defined as the sudden cessation of effective cardiac pumping function as a result of either ventricular asystole (inactivity of the heart) or pulseless ventricular tachycardia/ventricular fibrillation (VT/VF). Pulseless ventricular tachycardia/ventricular fibrillation is an abnormal electrical activity of the ventricles of the heart. Rapid diagnosis and treatment are essential because first, more than a few minutes of total CA results in permanent damage to the brain due to lack of oxygen, and second, the success of resuscitative measures is related to the rapidity with which they are instituted following arrest. For a person in VT/VF the probability of successful defibrillation and subsequent survival to hospital discharge is directly and negatively related to the interval between onset of VT/VF and delivery of first shock.
Comparison: By using AECDs we will evaluate if an automatic, rapid, accurate and specific diagnostic technology will further increase the rate of survival in patients with VT/VF by rapid and automatic defibrillation, independent of operator initiation, as compared to standard cardiopulmonary resuscitation (CPR) with conventional defibrillators initiated by healthcare providers. This trial will be a randomized, controlled trial and will test if AECDs can improve outcome measures when compared to traditional responses.
Conventional defibrillators are manually operated defibrillators that have to be attached to the patient and operated by a healthcare provider or layperson. In contrast, the purpose of AECDs is to automatically detect life-threatening arrhythmias and deliver external shocks according to a programmable prescription for hospitalized patients, who may be at transient risk for the development of life-threatening arrhythmias. AECDs immediately and automatically monitor, detect and treat cardiac arrhythmias with no human intervention. The AECD proposed to be utilized in this trial, PowerHeart CRM, a product of Cardiac Science, Inc, has been evaluated in the hospital setting to assess safety and efficacy, and has been approved by the FDA to be prophylactically attached to hospital patients and provide automatic defibrillation therapy without human intervention.
All patients admitted to the telemetry unit will be asked to volunteer for this study. Up to 3,000 patients will be asked to volunteer in this study during their stay in the telemetry unit. This study will evaluate if there is a way to improve survival in CA by comparing two groups
Group 1: This group includes patients admitted to telemetry unit who will undergo standard measures of CPR in case cardiac arrest is suspected.
Group 2: This group includes patients admitted to telemetry unit who will have an AECD attached to the chest wall and who will also undergo standard measures of CPR in case of cardiac arrest.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Atlanta Veterans Adminstration Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients admitted to telemetry ward and emergency department
- Age > 18 years.
Exclusion Criteria:
- Pregnant women
- Patients with R wave less than 0.5 millivolts.
- Patients with functioning Internal Cardiac Device.
- Patients with cardiac pacemakers if oversensing by AECD is demonstrated (double counting of pacer spikes).
- Patients with visible chest lesions that would prevent AECD pad placement.
- Patients who are designated Do Not Resuscitate.
- Right bundle branch block.
- Patients with Parkinson's disease.
- Patients with seizure disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Standard of Care Group
Patients will receive standard of care measures in case of cardiac arrest.
They will not receive AECD monitoring or intervention
|
|
EXPERIMENTAL: AECD Monitoring + Standard of Care Group
Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital.
Defibrillation of pulseless VT/VF by AECD.
|
In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation.
Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention.
The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Without Defibrillation
Time Frame: 10 minutes
|
Time to defibrillation: interval between onset of VT/VF and delivery of first shock.
Expected time to defibrillation for AECD group: 30±30 seconds; expected time to defibrillation for Standard of Care group: 180±180.
|
10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Abnormal Rhythms Monitored by the AECD
Time Frame: During the duration of hospital admission on the telemetry ward.
|
During the duration of hospital admission on the telemetry ward.
|
|
Survival to Discharge
Time Frame: At discharge
|
At discharge
|
|
Cerebral Performance at Discharge
Time Frame: At discharge
|
Cerebral Performance Categories/CPC scale: CPC 1: Good cerebral performance - conscious, alert, able to work, might have mild neurologic or psychological deficit. CPC 2: Moderate cerebral disability - conscious, sufficient cerebral function for independent activities of daily life. Able to work in sheltered environment. CPC 3: Severe cerebral disability - conscious, dependent on others for daily support because of impaired brain function. Ranges from ambulatory state to severe dementia or paralysis. CPC 4: Coma or vegetative state - any degree of coma without the presence of all brain death criteria. Unawareness, even if appears awake (vegetative state) without interaction with environment; may have spontaneous eye opening and sleep/awake cycles. Cerebral unresponsiveness. CPC 5: Brain death - apnea, areflexia, electroencephalogram (EEG) silence, etc. |
At discharge
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: A. Maziar Zafari, M.D., Ph.D, Division of Cardiology, Atlanta Veterans Adminstration Medical Center/ Emory University, Decatur, GA
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1216-2004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventricular Fibrillation
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Enrolling by invitationShort-coupled Idiopathic Ventricular FibrillationNetherlands
-
Guidant CorporationBoston Scientific CorporationCompletedHeart Failure | Ventricular Tachycardia, Ventricular FibrillationIsrael, Denmark
-
Boston Scientific CorporationCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular TachycardiaUnited States, Netherlands
-
Biosense Webster, Inc.CompletedVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexCroatia, Italy, Israel
-
Biosense Webster, Inc.CompletedVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexCroatia, Belgium, Italy
-
Mayo ClinicMedtronicCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Supraventricular TachycardiaUnited States, Israel
-
Institute for Clinical and Experimental MedicineRecruitingAtrial Fibrillation | Acute Heart Failure | Left Ventricular Dysfunction | Atrial Fibrillation RapidCzechia
-
University of Turin, ItalyUniversity of Padova; Centro Cardiologico Monzino; Policlinico Casilino ASL RMB; Humanitas Research Hospital IRCCS, Rozzano-MilanUnknownPersistent Atrial Fibrillation | Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction
-
Abbott Medical DevicesCompletedVentricular Tachycardia | Persistent Atrial FibrillationCanada, South Africa, Denmark, Australia, Italy, Austria, France, Germany, Netherlands, Portugal, Spain
-
Ottawa Heart Institute Research CorporationNot yet recruitingVentricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmias | Recurrent Ventricular Tachycardia
Clinical Trials on Defibrillation of pulseless VT/VF by AECD
-
Medtronic Cardiac Rhythm and Heart FailureCompletedTachycardia | Ventricular ArrhythmiasTaiwan, Belgium, Canada, United States, Hungary, New Zealand, Spain, Netherlands, United Kingdom, Poland, Australia, Hong Kong
-
Medtronic Cardiac Rhythm and Heart FailureTerminated